LexDanaLexDanabeta
Inventor

Jürgen Dinges

Inventor
North Chicago, IL, US

Overview

30→
Patents
2002–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 30 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary
C07DHeterocyclic compounds35%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations32%
A61KPreparations for medical, dental or toiletry purposes19%
C07CAcyclic or carbocyclic compounds13%
C02FTreatment of water, waste water, sewage, or sludge1%
PatentTitleYear
11,104,592Water treatment system202110,556,914Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use202010,308,610Inhibitor compounds of phosphodiesterase type 10A20199,938,269Inhibitor compounds of phosphodiesterase type 10A20189,856,220'Inhibitor compounds of phosphodiesterase type 10A'20189,657,034'Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors'20179,475,808'Inhibitor compounds of phosphodiesterase type 10A'20169,464,072'Treatment of central nervous system disorders'20169,388,148'Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor'20169,388,141'Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor'20169,376,396'Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor'20169,290,444'Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme'20169,273,068'Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A'20169,200,005'Inhibitor compounds of phosphodiesterase type 10A'20159,163,019'Inhibitor compounds of phosphodiesterase type 10A'20158,993,632'Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme'20158,940,902'Treatment of central nervous system disorders'20158,716,345'Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme'20148,198,331'Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme'20127,754,886'N-acylsulfonamide apoptosis promoters'20107,671,076'Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)'20107,528,282'Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme'20097,511,175'Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme'20097,504,512'N-acylsulfonamide apoptosis promoters'20097,468,371'Tricyclic pyrazole kinase inhibitors'20087,348,346'Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)'20087,217,838'Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme'20076,831,175'Kinase inhibitors'20046,720,338'N-acylsulfonamide apoptosis promoters'20046,495,576'Aminal diones as potassium channel openers'2002

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2002–2012Patents assigned to ABBOTT LAB (12)· patent assignee history
2002–2010Based in Grayslake, IL, US· patent location history
2007–2016Based in Wadsworth, IL, US· patent location history
2012–2015Patents assigned to BITNER R SCOTT (4)· patent assignee history
2012–2015Patents assigned to BROWMAN KAITLIN E (4)· patent assignee history
2014–2020Patents assigned to ABBVIE INC (17)· patent assignee history
2015–2020Patents assigned to ABBVIE DEUTSCHLAND (12)· patent assignee history
2015–2020Based in North Chicago, IL, US· patent location history
2021Based in Tallahassee, FL, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
ABBVIE INC172014–2020
ABBOTT LAB122002–2012
ABBVIE DEUTSCHLAND122015–2020
BITNER R SCOTT42012–2015
BROWMAN KAITLIN E42012–2015
Locations
LocationPatentsSpan
North Chicago, Illinois, US122015–2020
Wadsworth, Illinois, US102007–2016
Grayslake, Illinois, US72002–2010
Tallahassee, Florida, US12021